Acknowledgements:
The authors would like to thank all the patients and investigators that
participated in the studies. The author would like to thank John N.
Ratchford for his contributions to the inebilizumab program. The authors
would like to acknowledge Kamille O’Connor, Xiaoying Yu and Rouletta
Blowers of Amador Bioscience (Pleasanton, CA, USA) for assistance with
preparation of this manuscript.